Abstract Library

#4657 Should we use the growth modulation index (GMI) in response assessment in G2 neuroendocrine tumours (NETs)?

Introduction: Grade 2 (G2) neuroendocrine tumours (NETs) exhibit diverse behaviours ranging from indolent to aggressive malignancies. Growth Modulation Index (GMI) is the ratio between time to progression (TTP) with a line of therapy (TTPn) and that of the previous line of therapy (TTPn-1). A GMI value equal to or greater than 1,33 has been suggested as an indicator of clinical effectiveness beyond traditional metrics.

Conference:

Presenting Author: Bertuzzi A

Authors: Bertuzzi A, Ferrillo G, Laffi A, Evangelista L, Jandric J,

Keywords: growth modulation index (GMI), G2 gastroenteropancreatic neuroendocrine tumour (GEP-NET), tumour response assessment,

#4509 Epidemiological characteristics and prognosis analysis of gastric cancer (GC) with neuroendocrine differentiation (NED)

Introduction: GC with NED exhibits distinct biological characteristics, yet research on its clinical features and prognosis remains limited.

Conference:

Presenting Author: Zhang J

Authors: Huang Z, Li J, Wang C, Shen Y, Rao S,

Keywords: gastric cancer, neuroendocrine differentiation, Epidemiological characteristics, prognosis,

#3969 A case report of a high-grade pancreatic NET patient with high tumor mutation burden who benefited from chemotherapy combined with immunotherapy

Introduction: For patients with well-differentiated G3 NET, the efficacy of immune checkpoint inhibitors (ICIs) is currently not clear. The expression level of PD-L1 in tumor tissue, high microsatellite instability (MSI-H), and high tumor mutational burden (TMB-H) are considered indicators for selecting potential beneficiaries of immunotherapy.

Conference:

Presenting Author:

Authors: Jia X, Liang Y, Chen J,

Keywords: g3 pancreatic net, captem, tmb-h, icis,

#3660 Prognostic value of inflammation-related biomarkers in patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) – A systematic review and meta-analysis

Introduction: Hematological indicators of chronic systemic inflammation are among the most promising biomarkers for GEP-NENs, but their prognostic value remains controversial.

Conference:

Presenting Author: Yu F

Authors: Yu F, Cheng Z, Su F, Chen Y, Tan H,

Keywords: Gastroenteropancreatic neuroendocrine neoplasm, inflammation-related biomarker, prognostic value,

#3553 Gamma-glutamyltransferase as an indicator of hepatic tumor burden in neuroendocrine tumors

Introduction: In patients with neuroendocrine tumors (NETs) and liver metastasis, elevation of gamma-glutamyltransferase (GGT) is considered to be a sign of hepatic progression. However, there are no data supporting this assumption.

Conference:

Presenting Author: Schmidt B

Authors: Schmidt B, Leiderer M, Amin T, Viol F, Adam G,

Keywords: gamma glutamyltransferase, hepatic tumor burden, neuroendocrine tumor, liver metastasis, biomarker,